Last reviewed · How we verify
MK-1084
MK-1084 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system.
MK-1084 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system. Used for Chronic pain conditions (investigational), Chemotherapy-induced nausea and vomiting (CINV) (investigational).
At a glance
| Generic name | MK-1084 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | NK1 receptor antagonist |
| Target | NK1 receptor (neurokinin-1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Pain management / Oncology supportive care |
| Phase | Phase 3 |
Mechanism of action
NK1 receptor antagonism reduces the transmission of pain and emetic signals by blocking substance P, a neuropeptide involved in pain perception and nausea/vomiting pathways. This mechanism has been explored for chronic pain conditions and chemotherapy-induced nausea and vomiting (CINV).
Approved indications
- Chronic pain conditions (investigational)
- Chemotherapy-induced nausea and vomiting (CINV) (investigational)
Common side effects
- Headache
- Dizziness
- Nausea
Key clinical trials
- A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) (PHASE3)
- A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) (PHASE2)
- A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) (PHASE3)
- KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) (PHASE2)
- A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) (PHASE3)
- A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) (PHASE1, PHASE2)
- Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) (PHASE1)
- A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK-1084 CI brief — competitive landscape report
- MK-1084 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI